Cholesterol drug market heating up with new entrant

07/19/2004 | Financial Times (free content)

If the FDA gives its approval this week, a new competitor will enter the $25 billion to $35 billion market for lowering cholesterol. With that approval, Vytorin, from Schering-Plough and Merck, would be joining Crestor, from AstraZeneca, in trying to take market share away from Pfizer's Lipitor. Vytorin is a combination of Zocor and Zetia and is seen as the strongest Lipitor competitor, with a study this year showing it reduced cholesterol more effectively than Lipitor.

View Full Article in:

Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD